Option chain shows key data for Neuraxis's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Neuraxis.

Neuraxis (AMEX:NRXS) Stock, Option Chain

Neuraxis

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AGIL

AMPH

ASTI

AVTX

BITF

BOWL

BTBT

CASY

CGNT

CMRA

CXAI

DTSS

EZGO

GDEV

HUMA

IBRX

MDAI

MLTX

MTRX

NRXS

NVOS

OCTO

OFIX

ORCL

PERI

RIOT

RKLB

SDIG

SFWL

SGHT

SKIN

SLRN

STKH

TLRY

TNON

VERB

WULF

Gainers


	Tenon Medical, Inc.  (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.


Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Health Care

Market-Moving Exclusives

Exclusives

General

NeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research.

EXCLUSIVE: NeurAxis&#39; Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome

NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-conc

EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids

Neuraxis Inc

Earnings

Press Releases

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

NeurAxis Inc. Issues Letter to Shareholders

NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States

UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States

NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025

NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

Comments

Neuraxis

Neuraxis (NRXS) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell